BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND AXIN1, LA16c-314G4_3, 8312, ENSG00000103126, O15169, AXIN, MGC52315 AND Clinical Outcome
920 results:

  • 1. clinical and Imaging Characteristics of SARS-CoV-2 Breakthrough Infection in Hospitalized Immunocompromised Patients.
    Lee JE; Kim J; Hwang M; Kim YH; Chung MJ; Jeong WG; Jeong YJ
    Korean J Radiol; 2024 May; 25(5):481-492. PubMed ID: 38627873
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Remote Monitoring and Data Collection for Decentralized clinical Trials.
    Daly B; Brawley OW; Gospodarowicz MK; Olopade OI; Fashoyin-Aje L; Smart VW; Chang IF; Tendler CL; Kim G; Fuchs CS; Beg MS; Zhang L; Legos JJ; Duran CO; Kalidas C; Qian J; Finnegan J; Pilarski P; Keane H; Shen J; Silverstein A; Wu YL; Pazdur R; Li BT
    JAMA Netw Open; 2024 Apr; 7(4):e246228. PubMed ID: 38607626
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Prognostic impact of age in advanced non-small cell lung cancer patients undergoing first-line checkpoint inhibitor immunotherapy and chemotherapy treatment.
    Huang X; Wu S; Chen S; Qiu M; Zhao Y; Wei J; He J; Zhao W; Tan L; Su C; Zhou S
    Int Immunopharmacol; 2024 May; 132():111901. PubMed ID: 38554448
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Spreading Through Air Spaces And Thinking About lung Metastases.
    M Castro P; Rei J; Silva C; Miranda J; Guerra M
    Port J Card Thorac Vasc Surg; 2023 Oct; 30(3):31-35. PubMed ID: 38499034
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer.
    Lang C; Megyesfalvi Z; Lantos A; Oberndorfer F; Hoda MA; Solta A; Ferencz B; Fillinger J; Solyom-Tisza A; Querner AS; Egger F; Boettiger K; Klikovits T; Timelthaler G; Renyi-Vamos F; Aigner C; Hoetzenecker K; Laszlo V; Schelch K; Dome B
    World J Surg Oncol; 2024 Feb; 22(1):57. PubMed ID: 38369463
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Dynamic immune signatures of patients with advanced non-small-cell lung cancer for infection prediction after immunotherapy.
    Luo YH; Shen CI; Chiang CL; Huang HC; Chen YM
    Front Immunol; 2024; 15():1269253. PubMed ID: 38343550
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A novel investigation into the negative impact of opioid use on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
    Guo H; Li Y; Lin J; Li D; Yang J; Wang J; Mao J; Wang Y; Yan X
    Int Immunopharmacol; 2024 Mar; 129():111611. PubMed ID: 38325047
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
    Liu JS; Cai YX; He YZ; Xu J; Tian SF; Li ZQ
    BMC Cancer; 2024 Jan; 24(1):123. PubMed ID: 38267913
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Bacteria and bacteriophage consortia are associated with protective intestinal metabolites in patients receiving stem cell transplantation.
    Thiele Orberg E; Meedt E; Hiergeist A; Xue J; Heinrich P; Ru J; Ghimire S; Miltiadous O; Lindner S; Tiefgraber M; Göldel S; Eismann T; Schwarz A; Göttert S; Jarosch S; Steiger K; Schulz C; Gigl M; Fischer JC; Janssen KP; Quante M; Heidegger S; Herhaus P; Verbeek M; Ruland J; van den Brink MRM; Weber D; Edinger M; Wolff D; Busch DH; Kleigrewe K; Herr W; Bassermann F; Gessner A; Deng L; Holler E; Poeck H
    Nat Cancer; 2024 Jan; 5(1):187-208. PubMed ID: 38172339
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Sarcomas With RAD51B Fusions Are Associated With a Heterogeneous Phenotype.
    Chang HY; Dermawan J; Sharma A; Dickson B; Turashvili G; Torrence D; Nucci M; Chiang S; Oliva E; Kirchner M; Stenzinger A; Mechtersheimer G; Antonescu C
    Mod Pathol; 2024 Feb; 37(2):100402. PubMed ID: 38141829
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Circulating Immune Proteins: Improving the Diagnosis and clinical outcome in Advanced Non-Small Cell lung cancer.
    Torres-Martínez S; Calabuig-Fariñas S; Gallach S; Mosqueda M; Munera-Maravilla E; Sirera R; Navarro L; Blasco A; Camps C; Jantus-Lewintre E
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139416
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [clinical analysis of lung adenocarcinoma with epidermal growth factor receptor mutation transformed into sarcoma].
    Zhu QQ; Du MZ; Wu WT; Guo LC; Huang JA; Shen D
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Jan; 47(1):24-30. PubMed ID: 38062690
    [No Abstract]    [Full Text] [Related]  

  • 14. Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy.
    Lin R; Mallick AB; Wang ZX; Brown SA; Lu B; Jiang W
    Diagn Pathol; 2023 Oct; 18(1):116. PubMed ID: 37865792
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse outcomes in Patients With EGFR-Mutant lung cancer.
    Stockhammer P; Grant M; Wurtz A; Foggetti G; Expósito F; Gu J; Zhao H; Choi J; Chung S; Li F; Walther Z; Dietz J; Duffield E; Gettinger S; Politi K; Goldberg SB
    J Thorac Oncol; 2024 Feb; 19(2):240-251. PubMed ID: 37806385
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Thyroid transcription factor-1 expression in lung neuroendocrine tumours: a gender-related biomarker?
    La Salvia A; Siciliani A; Rinzivillo M; Verrico M; Baldelli R; Puliani G; Modica R; Zanata I; Persano I; Fanciulli G; Bassi M; Mancini M; Bellino S; Giannetta E; Ibrahim M; Panzuto F; Brizzi MP; Faggiano A
    Endocrine; 2024 Feb; 83(2):519-526. PubMed ID: 37775725
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors.
    Fujikawa K; Saito T; Kurose K; Kojima T; Funakoshi T; Sato E; Kakimi K; Iida S; Doki Y; Oka M; Ueda R; Wada H
    PLoS One; 2023; 18(9):e0291772. PubMed ID: 37729184
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Efficacy of Tyrosine Kinase Inhibitors in Primary Driver-Gene-Positive Combined Small-Cell lung cancer: A Retrospective Study.
    Shi Z; Wei J; Sun W; Zeng X; Zhou H; Song Z
    Clin Lung Cancer; 2023 Dec; 24(8):717-725.e1. PubMed ID: 37482500
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Identification of age- and immune-related gene signatures for clinical outcome prediction in lung adenocarcinoma.
    Zhou A; Zhang D; Kang X; Brooks JD
    Cancer Med; 2023 Aug; 12(16):17475-17490. PubMed ID: 37434467
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study.
    Nicholson BD; Oke J; Virdee PS; Harris DA; O'Doherty C; Park JE; Hamady Z; Sehgal V; Millar A; Medley L; Tonner S; Vargova M; Engonidou L; Riahi K; Luan Y; Hiom S; Kumar H; Nandani H; Kurtzman KN; Yu LM; Freestone C; Pearson S; Hobbs FR; Perera R; Middleton MR
    Lancet Oncol; 2023 Jul; 24(7):733-743. PubMed ID: 37352875
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 46.